Status:
COMPLETED
Evaluation of cfDNA as a Marker of Response in Rectal Cancer
Lead Sponsor:
Hospital Pedro Hispano
Collaborating Sponsors:
Diogo Melo Pinto, MD, Hospital Pedro Hispano
Telma Fonseca, MD, Centro Hospitalar de São João
Conditions:
Cancer of Rectum
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A pathological complete response (pCR) after surgery occurs in approximately 20% of rectal cancer patients submitted to neoadjuvant chemotherapy, with apparent survival benefit. This group could, pote...
Eligibility Criteria
Inclusion
- Patients aged over 18 years old, ECOG 0-2
- High-risk patients with biopsy proven rectal adenocarcinoma who will undergo long-course chemoradiotherapy and who are potentially eligible for curative surgery
- Patients who can fully understand the content of the informed consent form and sign it upon their own opinion
- Patients who can coordinate with the researchers to undergo the long-term post-treatment rechecks and follow-up
Exclusion
- Patient has any underlying or current medical condition, which would interfere with the evaluation of the patient (e.g., end-stage liver disease, pulmonary hypertension, systemic lupus erythematosus etc.).
- Patient has severe mental illness.
- Patient has any other conditions, which would interfere with the evaluation of the subject.
Key Trial Info
Start Date :
November 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04319354
Start Date
November 18 2019
End Date
December 30 2021
Last Update
May 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Pedro Hispano
Matosinhos Municipality, Porto District, Portugal, 4464-513